Actinium Pharmaceuticals (ATNM) Stock Price Down 11.7%
Actinium Pharmaceuticals Inc (NYSEAMERICAN:ATNM)’s share price traded down 11.7% during mid-day trading on Monday . The company traded as low as $0.47 and last traded at $0.48. 1,319,186 shares changed hands during trading, an increase of 72% from the average session volume of 766,801 shares. The stock had previously closed at $0.54.
A number of equities analysts have recently issued reports on the company. Oppenheimer set a $5.00 price target on Actinium Pharmaceuticals and gave the stock a “buy” rating in a research report on Tuesday, February 26th. Zacks Investment Research raised Actinium Pharmaceuticals from a “hold” rating to a “buy” rating and set a $0.50 price target on the stock in a research report on Monday, April 1st. Finally, Maxim Group set a $3.00 price target on Actinium Pharmaceuticals and gave the stock a “buy” rating in a research report on Tuesday, February 5th. Five investment analysts have rated the stock with a buy rating, The stock presently has an average rating of “Buy” and an average target price of $3.50.
Actinium Pharmaceuticals (NYSEAMERICAN:ATNM) last released its earnings results on Tuesday, March 19th. The biotechnology company reported ($0.06) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.06).
Actinium Pharmaceuticals Company Profile (NYSEAMERICAN:ATNM)
Actinium Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops targeted therapies for patients with cancers lacking effective treatment options. Its lead product candidate is Iomab-B that is in Phase III clinical studies for myeloablation and conditioning of the bone marrow prior to a bone marrow transplant for patients with relapsed or refractory acute myeloid leukemia (AML) age 55 and older.
Further Reading: How liquidity affects the bid-ask spread
Receive News & Ratings for Actinium Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Actinium Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.